Advanced Biohealing
Advanced BioHealing, Inc. was a regenerative medicine company best known for Dermagraft, a cryopreserved human fibroblast-derived dermal substitute used to treat diabetic foot ulcers. The company acquired the Dermagraft assets from Smith & Nephew in 2006, was backed by Canaan Partners and other venture investors, and was acquired by Shire plc for $750 million in cash in June 2011 to seed Shire's regenerative medicine business unit. Dermagraft was later sold to Organogenesis in 2014. Advanced BioHealing no longer operates as an independent entity and publishes no public developer portal, API, or programmatic surface; this profile is retained in the API Evangelist network as a venture-portfolio company record.
Advanced Biohealing is profiled on the APIs.io network. Tagged areas include Company, Regenerative Medicine, Biotechnology, Medical Devices, and Healthcare.
scored 2026-11-06 · rubric v0.27.0 · Show this score on your site →
Kin Score
Kin Score
How this is scored →scored 2026-11-06 · rubric v0.27.0
<a href="https://apis.io/providers/advanced-biohealing/"><img src="https://apis.io/badge/advanced-biohealing/card.svg" alt="Advanced Biohealing on APIs.io — Kin Score by API Evangelist"></a>Other styles, a README pill and a shields.io endpoint are on the badge page.
- Machine-Readable Contract +18 pts — api_specs includes an OpenAPI document
- MCP Server +12 pts — deployment.mode + probe verdict on the mcp/ manifest, not the pointer; an unprobed slug falls back to authorship
- Agentic Access Contract +10 pts — agentic_access artifact present (x-agentic-access), graded by author
- Machine-Readable Auth +10 pts — a served openid-configuration/oauth-authorization-server carrying `issuer` (served), else the securitySchemes class in the provider OpenAPIs — bound (mutualTLS, DPoP, Signature) > negotiable (oauth2 authorizationCode/clientCredentials, openIdConnect) > bearer (http bearer, apiKey)
- Idempotency +9 pts — OpenAPI mutating operations declare an idempotency key — a header, a request-body property, or a named de-duplication token whose own description says so (verified); else common[].type matches /idempoten/i (documented)
- Stable Error Semantics +8 pts — OpenAPI $refs a shared error schema across 4xx/5xx responses (verified), else common[].type includes ErrorCatalog / ErrorCodes / DeclineCodes
- Contract Quality scores 0.0 — up to +25.0 composite points
- Developer Ergonomics scores 0.0 — up to +20.0 composite points
- Access Clarity scores 0.0 — up to +20.0 composite points
Source (apis.yml)
aid: advanced-biohealing
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source: []
generated: '2026-11-06'
method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/advanced-biohealing.png
name: Advanced Biohealing
description: Advanced BioHealing, Inc. was a regenerative medicine company best known for Dermagraft, a cryopreserved human
fibroblast-derived dermal substitute used to treat diabetic foot ulcers. The company acquired the Dermagraft assets from
Smith & Nephew in 2006, was backed by Canaan Partners and other venture investors, and was acquired by Shire plc for $750
million in cash in June 2011 to seed Shire's regenerative medicine business unit. Dermagraft was later sold to Organogenesis
in 2014. Advanced BioHealing no longer operates as an independent entity and publishes no public developer portal, API,
or programmatic surface; this profile is retained in the API Evangelist network as a venture-portfolio company record.
url: https://raw.githubusercontent.com/api-evangelist/advanced-biohealing/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-17'
tags:
- Company
- Regenerative Medicine
- Biotechnology
- Medical Devices
- Healthcare
- Wound Care
- Life Sciences
- Venture Portfolio
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
x-enrichment:
date: '2026-07-19'
status: backfilled
pass: local-v1
note: backfilled from .gitignore signal + verified work evidence
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.
MCP server
One button, every client — Claude, Cursor, VS Code and the rest.
https://apis.io/mcp
Tools for providers
9 MCP tools reach this
find_providersBrowse and filter every provider in the catalog.get_provider_artifactsEvery artifact this provider publishes, grouped by type.get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.get_provider_toolsEvery MCP tool they ship, with the operation each wraps.get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.get_provider_ratingPRO — composite, band, trend and facet scores.apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.resolveTurn a domain, URL or GitHub org into the provider it belongs to.find_cohortsEvery scored population of providers in the catalog.
Call it yourself
curl for this page
curl "https://apis.io/api/v1/providers/advanced-biohealing"
curl "https://apis.io/api/v1/providers?limit=25"
curl "https://apis.io/api/v1/providers/advanced-biohealing/operations?limit=25"
curl "https://apis.io/api/v1/providers/advanced-biohealing/evidence"
Calls without X-API-Key need no key. Calls with it need a paid plan — get a key.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we store it to create your key and to recognise you if you sign in with another provider. See our Privacy Policy and Terms.
A second provider on the same verified email joins the account you already have.